Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2018-05-08 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
第八届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the sixth meeting of the eighth Supervisory Board of the company, including the election of the Supervisory Board Chairman and the chairman's biography. It contains no financial data, no financial statements, no earnings information, no audit details, and no regulatory certifications. It is a corporate governance-related announcement about board composition changes. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1206 characters), and it is not an announcement of a report publication or a certification. Hence, the classification is MANG with high confidence.
2018-05-08 Chinese
关于召开2017年年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2017 Annual General Meeting (AGM) of Chengdu Berry Genomics Co., Ltd. It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on (such as the 2017 annual report, financial statements, board reports, profit distribution plan, appointment of auditors, and board member nominations), registration details, and proxy voting instructions. The document does not contain the actual annual report or financial statements but rather serves as a notice and instructions for shareholders to participate in the AGM and vote on various proposals. The document length is about 4861 characters, which is consistent with a detailed AGM notice rather than the full annual report or other financial filings. Therefore, this document fits the category of AGM Information (AGM-R).
2018-05-03 Chinese
第八届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th meeting of the 8th Board of Directors of the company. It includes voting results on specific proposals related to subsidiary capital increase rights and subscription agreements. The text emphasizes the board meeting procedures, voting outcomes, and references to related announcements. There is no detailed financial data, quarterly or annual report content, or audit information. The document is clearly a Board/Management Information announcement about board decisions and management actions rather than a financial report or regulatory filing. The document length is short and focused on board resolutions, fitting the Board/Management Information category.
2018-05-02 Chinese
独立董事对第八届董事会第十一次会议相关事项的事前认可意见和独立意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval and independent opinions on specific board meeting agenda items related to a transaction involving the company's subsidiary and Healthcare Ventures Holdings Limited. It discusses the reasonableness of the transaction pricing, compliance with stock exchange listing rules, and the impact on shareholder interests. The content focuses on board-level approval and opinions on corporate transactions rather than financial results, audit opinions, or regulatory filings. The document is not a full report but rather a formal board/management information disclosure about a transaction and related board meeting matters. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short (1026 characters), and it is not an announcement of a report publication or a certification letter, so RPA or RNS are not appropriate.
2018-05-02 Chinese
关于放弃子公司增资扩股优先认缴权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's decision to waive its preemptive rights to subscribe for additional shares in a subsidiary, detailing the transaction structure, financing parties, shareholding changes, and board approvals. It includes financial data of the subsidiary and strategic rationale for the transaction. There is no indication that this is a full financial report, audit report, or earnings release. It is a specific corporate transaction update related to capital raising and shareholding changes in a subsidiary. This fits the definition of a Capital/Financing Update (CAP). The document length is over 6000 characters and contains substantive details about the financing transaction, not just a brief notice or report publication announcement.
2018-05-02 Chinese
2018年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 First Quarter Report" of the company 成都市贝瑞和康基因技术股份有限公司. It contains detailed financial data for the first quarter of 2018, including revenue, net profit, earnings per share, asset and equity figures, and other financial indicators. It also includes shareholder information and notes on financial changes and forecasts for the next half year. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is about 5993 characters, which is sufficient to contain substantive financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2018
2018-04-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.